Immunogenicity of the biosimilar CT-P13 infliximab or the original infliximab in Iraqi patients with Ankylosing spondylitis does not correlate with their demographic characteristics
Background: Ankylosing spondylitis is a rare disease affecting people with hereditary factors. Its treatment includes life style modification and use of drugs such as the biologic agent infliximab or its biosimilar, CT-P13 infliximab. Despite their therapeutic usefulness, these agents are associate...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
College of Medicine University of Baghdad
2023-01-01
|
| Series: | مجلة كلية الطب |
| Online Access: | https://iqjmc.uobaghdad.edu.iq/index.php/19JFacMedBaghdad36/article/view/1969 |